Hormone Level Reduction1
Sandostatin® LAR® delivers effective control of both GH and IGF-1 levels1
Symptom Control2
Sandostatin® LAR® provides symptom control in acromegaly (N=151)2
Symptom control is an important therapeutic goal in acromegaly.3
Sandostatin® LAR® delivers significant improvement in 5 common symptoms of acromegaly.2
Tumor Shrinkage
In two clinical studies, Sandostatin® LAR® demonstrated reductions in tumor size in patients with acromegaly.1,4
Significant tumor reduction (≥20%) was experienced in one study of previously untreated patients (n=68)4
In another study (n=43), tumor shrinkage was observed in1
No patients experienced an increase in tumor volume while on treatment with Sandostatin® LAR® outside the ±20% measurement error.4,5
References:
1. Cozzi R, Attanasio R, Montini M, et al. Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? J Clin Endocrinol Metab. 2003;88(7):3090-3098. 2. Lancranjan I, Atkinson AB; the Sandostatin® LAR® Group. Results of a European multicentre study with Sandostatin® LAR® in acromegalic patients. Pituitary. 1999;1(2):105-114. 3. Schöfl C, Franz H, Grussendorf M, et al; participants of the German Acromegaly Register. Long-term outcome in patients with acromegaly: analysis of 1344 patients from the German Acromegaly Register. Eur J Endocrinol. 2013;168(1):39-47. 4. Mercado M, Borges F, Bouterfa H, et al; the SMS995B2401 Study Group. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol (Oxf). 2007;66(6):859-868. 5. Colao A, Ferone D, Marzullo P, et al. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab. 2001;86(6):2779-2786.
Please see the Summary of Product Characteristics.